Destination

2025-03-24

Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.

Read more...

[...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination

2025-03-07

Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]

Match Score: 193.03

Destination

2025-01-03

The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 176.77

Destination

2025-03-27

Wegovy sales took a hit this year. Novo's CEO blames off-brand competition

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giantâ [...]

Match Score: 164.27

thenextweb

2025-01-10

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 160.99

Destination

2025-03-28

Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup

Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection [...]

Match Score: 143.54

Destination

2025-03-10

Novo Nordisk's Ozempic successor disappointed Wall Street again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more... [...]

Match Score: 103.65

Destination

2025-02-28

Engadget Podcast: iPhone 16e review and Amazon's AI-powered Alexa+

The keyword for the iPhone 16e seems to be "compromise." In this episode, Devindra chats with Cherlynn about her iPhone 16e review and try to figure out who this phone is actually for. Also, [...]

Match Score: 83.47

thenextweb

2025-03-24

SAP becomes Europe’s most valuable company, ASML holds fourth place

Just five months after surpassing ASML, German software giant SAP has overtaken Novo Nordisk to become Europe’s most valuable listed company. SAP’s shares rose 1.6% on Monday, bringing its market [...]

Match Score: 77.34

Destination

2025-01-13

The King of Ozempic Is Scared as Hell

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics? [...]

Match Score: 73.42